Archive - Biotech Blueprint

Lilly Bets on AI, Prasad Returns, and Brinsupri Breaks Through — This Week in Biotech #65

Plus: The latest on Sarepta’s financial strategy, Insmed’s lung disease win, and Schrödinger’s early-stage setback (August 8–14, 2025).

Aug 15 •

Katerina Roznik

and

Erin Mihealsick

RFK Jr. Ends mRNA Funding, Sarepta Beats Q2, and Eli Lilly Falls — This Week in Biotech #64

Biotech Q2 round-up: Sarepta rebounds, Eli Lilly’s oral GLP-1 disappoints, and U.S. vaccine strategy pivots away from mRNA (August 1–7, 2025).

Aug 8 •

Katerina Roznik

FDA Shake Up, Sarepta Rebounds, and Trump Targets Drug Prices — This Week in Biotech #63

Prasad’s resignation boosts biotech stocks, Sarepta regains ground, and Trump demands global price matching from pharma CEOs (July 25–31, 2025).

Aug 1 •

Katerina Roznik

and

Erin Mihealsick

July 2025

Sarepta, Elevidys, and the Future of AAV Gene Therapy

Part 2 of a mini-series on gene therapies, from the perspective of a scientist and an investor.

Jul 29 •

Katerina Roznik

and

The Biotech Capital Compass

Sarepta’s Gene Therapy Crisis Deepens — This Week in Biotech #62

FDA setbacks, insider buys, trial wins, and pipeline pivots (July 18–24, 2025).

Jul 25 •

Katerina Roznik

and

Erin Mihealsick

Sarepta’s $400M Pivot, MiNK’s 500% Surge, and AML Breakthroughs — This Week in Biotech #61

Layoffs, CRLs, and standout trial data from Sarepta, MiNK, SELLAS, DiaMedica, and more (July 11–17, 2025).

Jul 18 •

Katerina Roznik

and

Erin Mihealsick

CRISPR in 2025: Clinical Use, Regulatory Pressure, and Future Promise

Part 1 of a mini-series on gene therapies, from the perspective of a scientist and an investor.

Jul 17 •

Katerina Roznik

KalVista’s FDA Win, Merck’s $10B Deal, and CRISPR Momentum — This Week in Biotech #60

FDA nods, big M&A, and major trial wins (July 3–10, 2025).

Jul 11 •

Katerina Roznik

and

Erin Mihealsick

Sparks Fly in Biotech — This Week in Biotech #59

Bispecifics, macrocycles, and in vivo CAR-T show targeted power in a volatile regulatory climate (June 27 – July 2, 2025).

Jul 3 •

Katerina Roznik

and

Erin Mihealsick

June 2025

FDA Drama & Psychedelic Setback — This Week in Biotech #58

FDA turmoil impacts key drug decisions, Compass’s phase 3 psilocybin data spooks investors, and Exelixis soars on cancer results (June 20–26, 2025).

Jun 27 •

Katerina Roznik

and

Erin Mihealsick

HIV Breakthrough & Gene Editing Deals — This Week in Biotech #57

Gilead’s HIV breakthrough, Lilly’s $1.3B gene editing deal, and FDA reform efforts (June 13–19, 2025).

Jun 20 •

Katerina Roznik

and

Erin Mihealsick

Biotech Caught Between AI Momentum and Political Turbulence — This Week in Biotech #56

Novo bets on AI drug discovery, RFK Jr. reshapes the CDC, and Congress targets $5B in pharma ad spending. Catch up on the latest biotech breakthroughs…

Jun 13 •

Katerina Roznik

and

Erin Mihealsick

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts